Roche Holding stock rises 2.1 percent at the close

At the close on September 22, 2026, Roche Holding stock gained 2.1 percent on the OTCQX after positive enicepatide Phase II data. Roche Pharma Day is scheduled for September 28, 2026.

Roche Holding stock gained 2.1 percent on the OTCQX on September 22, 2026, after the U.S.-listed ADRs closed at USD 55.30. The move followed positive Phase II data for enicepatide, which Roche said met both primary endpoints in adults with type 2 diabetes and overweight or obesity, as reported by Reuters.

September 22, 2026 after the data

Roche Holding AG (ISIN CH0012032048, OTCQX: RHHBY) had risen 2.1 percent by the U.S. close, compared with a 1.49 percent gain for the S&P 500 at 7,764.70. The ADR session followed a company announcement dated September 22, 2026, which described positive topline results from the CT-388-104 trial, according to Roche.

Roche reported that the highest enicepatide dose produced an average 15.5 percent reduction in body weight over 48 weeks, while 62 percent of participants reached non-diabetic blood sugar levels. Its shares on SIX had closed 0.9 percent lower at 11:35 a.m. ET, highlighting the different performance of the Swiss listing and the U.S. ADR.

Roche Pharma Day on September 28, 2026

Roche Pharma Day is scheduled for September 28, 2026, at 10:00 a.m. Swiss time, according to a Deutsche Boerse calendar notice reported on September 22, 2026 by Deutsche Boerse. The event is the next dated company-specific item in the available schedule.